Individuals with COVID-19 incur a greater risk of Cardiovascular Sequelae

The association of short-, medium and long-term cardiovascular sequelae with COVID-19 infection: a multinational pilot study


Background: Emerging evidence has reported that COVID-19 infection could lead to severe cardiovascular disorders and associated mortality.^{1,2} Nevertheless, the risk of cardiovascular sequelae associated COVID-19 infection remained inconclusive due to the large

variability in effect estimates and contrasting evidence in the risk association of certain diseases from existing studies which differs

in study design, selection of controls and the follow-up duration of these study.³

Figure 1. Flow diagram on the selection of study

population



COVID-19 and matched comparator

	Subjects	Follow-up (person-years)	Events	Hazard ratio (95% CI)	Calibrated hazard ratio (95% CI)	 Hazard Ratio Calibrated Hazard Rati
Angina						
Targets	17,296	14,918	35	Reference	Reference	
Comparators	128,711	110,983	142	1.31 (1.17–1.47)	0.98 (0.85-1.13)	
Arrhythmia						
Targets	16,454	14,030	349	Reference	Reference	
Comparators	122,267	104,592	1,917	1.30 (1.15-1.46)	0.97 (0.83-1.13)	
Myocardial infarction						
Targets	17,246	14,879	34	Reference	Reference	
Comparators	128,381	110,679	149	1.76 (1.17-2.58)	1.32 (0.88-1.98)	1
Heart failure						
Targets	17,168	14,804	86	Reference	Reference	
Comparators	127,727	110,073	415	1.36 (1.05-1.74)	1.02 (0.78-1.33)	
Hypertension						i de la companya de l
Targets	13,082	10,837	650	Reference	Reference	
Comparators	98,490	82,360	4,102	1.21 (1.10–1.32)	0.90 (0.79-1.02)	
Myocarditis and pericar	ditis					
Targets	17,363	14,972	36	Reference	Reference	
Comparators	129,209	111,432	115	2.22 (1.46-3.32)	1.66 (1.09-2.53)	
Endocarditis						
Targets	17,383	15,012	8	Reference	Reference	—
Comparators	129,400	111,631	34	1.62 (0.65-3.64)	1.00 (0.86-1.16)	
Cardiomyopathy						
Targets	17,357	14,989	15	Reference	Reference	• • • • • • • • • • • • • • • • • • •
Comparators	129,134	111,385	54	2.29 (1.19-4.12)	1.71 (0.91-3.20)	
Arteriosclerosis				. ,		
Targets	17,193	14,824	63	Reference	Reference	
Comparators	127,891	110,145	344	1.35 (1.00-1.78)	1.00 (0.74-1.36)	

Table 1. Preliminary results on the incidence rate, hazard ratio of cardiovascular sequelae between patients with

Hazard Ratio (HR) and 95% Confidence Interval (95% CI) were estimated by Cox regression, HR > 1 (or <1) indicates patients with COVID-19 had higher (lower) risk of sequelae compared to the 0 1 non-COVID-19 control cohort

Hazard ratio (95%CI)

Methods

		Table 2. Electronic health records consisted in databases mapped to the Observational Medical Outcomes Partnership (OMOP) common data model		
Study design	Data source	Database	Electronic health records	
Retrospective cohort	 Multinational healthcare databases 	US Open-claim IQVIA	Pre-adjudicated health insurance claims collected from general practitioners and specialists	
studyPropensity score	mapped to OMOP	Germany DA IQVIA ^a , France LPD IQVIA ^b	Proprietary practice management software used by genera practitioners and selected specialists	
matching	CDM (Table 2)	Italy LPD IQVIA ^b , UK IMRD IQVIA ^c	Patient records from general practitioners	
		^a DA = Disease Analyser, ^b LPD = Longitudinal Patient Database , ^c IMRD = IQVIA Medical Research Data		
Study population	Follow-up	 Preliminary analysis was conducted on the Italy LPD database between December 1st 2019–2022 		
Individuals with	 Short (Up to 6 months), Medium (6 months to 1 			
COVID-19 between		• The hazard ratio (HR) and 95% confidence interval (CI) of each outcome will be		
Dec 1 st 2019–20 and	year)	estimated using Cox proportional hazard regression.		
their matched controls	• Long term (1 to 3 years)	 Empirical calibration was performed based on negative control outcomes which were 		

• Empirical calibration was performed based on negative control outcomes which were not expected be associated with the COVID-19 infection

Conclusion: An increased risk of cardiovascular sequelae was observed amongst individuals

recovering from COVID-19 from our empirical findings. Evidence generated from this study could

generate highly generalizable evidence to aid clinical decision making and inform public health policy

[1]. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583-90. [2]. Wan EYF, Mathur S, Zhang R, Yan VKC, Lai FTT, Chui CSL, et al. Association of COVID-19 with short- and long-term risk of cardiovascular disease and mortality: a prospective cohort in UK Biobank. Cardiovasc Res. 2023. [3]. Peter RS, Nieters A, Krausslich HG, Brockmann SO, Gopel S, Kindle G, et al. Post-acute sequelae of covid-19 six to 12 months after infection: population based study. BMJ. 2022;379:e071050.

HKU Ned

Ivan C.H Lam, Yi Chai, Eric Y.F Wan, Celine S.L Chui, Xue Li, Carlos K.H Wong, Hao Luo, Kenneth K.C Man, Xiaoyu Lin, Can Yin, Jing Li, Mui Van Zandt, Sarah Seager, Ian C.K Wong* *Corresponding author

This work was supported by the Research Grants Council of Hong Kong under the Collaborative Research Fund Scheme (C7154-20G).



lami@hku.hk (Ivan C.H Lam)